<!-- PageNumber="99" -->
<!-- PageHeader="TREATMENT ADHERENCE BY BIPOLAR DISORDER PATIENTS" -->

of patient-reported nonadherence equivalent to major
defaulting on 20-30% of days would be needed to
accord with comparable nonadherence estimates of
6% of patients made by their physicians (Table 2).

These self-reports of incomplete adherence with
prescribed treatments for BPD in one-third of patients
are unverified, but the risk of under-reporting may be
limited by the very sensitive standard applied in an
effort to detect the "worst case" for incomplete
treatment-adherence. In addition to the self-reported,
recent incomplete treatment-adherence just noted,
32.9% [137/417] of patients also reported having
discontinued all recommended medications for BPD
at some point in the past, without informing their
physicians. Leading reasons given for such patient-
initiated discontinuation of treatment, among 130
patients providing such information, ranked: (a) not
needing it any longer (22.3%) > (b) no longer wanting
to take it (18.5%) > (c) side effects (13.1%]) > (d)
feeling better at the time (10.8%).

The rate of reported major defaulting in the past
(32.9%) and the rate of missing recent single doses
(33.8%) is similar, and many cases of previous and
current nonadherence (45.0%) involved the same
persons. Both rates represent about one-third of all
treated patients with BPD sampled, indicating that
some degree of treatment-nonadherence may be
quite prevalent among contemporary American
BPD patients. The apparently large disparity between
physicians' impressions and patient self-reports is
noteworthy, but may reflect differences in definitions
of "nonadherence," such that physicians self-defined
nonadherence was likely to reflect clinically important
levels of missed dosing over undefined periods of risk,
whereas patients were asked about even single missed
doses within 10 recent days.


# Patient assessments of illness and its treatment

When asked a general question about major frustrations
of having BPD, patients cited factors related to the
illness as well as its treatment (Table 3). Most
commonly cited major burdens involving ≥ 40% of
423 patients providing such data were: mood swings
(66.4%) > depression (56.3%) > need for daily self-
medication (51.1%) > stigma of being considered
mentally ill (43.5%) > uncertain interpersonal relationships
(40.4%) ≥ medication side-effects (40.2%).
Prominent adverse effects associated with treatment-
nonadherence, as identified by the 145 patients with
self-reported nonadherence, ranked: weight-gain
(58.5%) > excessive sedation (54.2%) > physical awkwardness
or tremor (33.1%).


Table 3. Major frustrations reported by BPD patients

| Characteristic | $$n \left( \right)$$ |
| - | - |
| Illness-related factors | |
| Mood swings | 281 (66.4) |
| Depressions | 238 (56.3) |
| Others' perceptions/stigma | 184 (43.5) |
| Problems with trust/relationships/social interactions | 171 (40.4) |
| Holding down a job | 152 (35.9) |
| Hospitalization | 118 (27.9) |
| Highs of mood | 115 (27.2) |
| Lack of information | 26 (6.15) |
| Treatment-related factors | |
| Taking medication every day | 216 (51.1) |
| Medication side-effects | 170 (40.2) |
| Cost of treatment | 3 (0.71) |
| Miscellaneous factors | |
| Other | 34 (8.04) |

Responding patients $\left( N = 423; 98.6 \right)$ cited four major frustrations/
person (1708/423).


## Physician assessments of treatment

When psychiatrists were asked to report improvements
in treatments for BPD patients needed to
increase acceptance and adherence to treatment,
the most common response was the need for better
mood-stabilization in 48.0% of their 429 patients. In
addition, they identified freedom from weight-gain as
important for treatment-acceptance among 29.1%
of their patients, and improvement of treatment-
unresponsive depression in 30.8%. They also estimated
that at least 59.0% of their BPD patients had
experienced adverse effects of psychotropic medications
at some time in the past, that adverse effects
were of current concern to 14.0% of patients (60/429),
and were considered by their physicians to be severe in
15.0% (9/60) of that subgroup. Psychiatrists reported
further that 30.5% of their 429 BPD patients had
experienced weight-gain in association with current
treatment, with substantial prevalence of hyperlipidemia
(19.1%) and diabetes (8.62%) and identified these
as problems of particular clinical concern.


## Univariate analyses of factors associated with treatment-nonadherence

We compared treatment-nonadherent with treatment-
adherent patients on a list of factors identified in the
PSF and PRF questionnaires, which yielded a total
of 59 variables tentatively related to treatment
adherence, based on initial univariate comparisons
$\left( p \leq 0 . 1 0 \right)$ , and 43 significantly $\left( p < 0 . 0 5 \right)$ associated

<!-- PageFooter="Hum. Psychopharmacol Clin Exp 2008; 23: 95-105. DOI: 10.1002/hup" -->
<!-- PageFooter="Copyright © 2007 John Wiley & Sons, Ltd." -->
```